Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "TC-210 Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The clinical landscape of ...

\\- TC-210 induced tumor regression in all of the first eight patients \\- Ovarian cancer patient achieved confirmed RECIST partial response (PR)\\- Overall response rate (ORR) 50% in patients ...

The Company’s lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small ...

The strategic partnership will focus on the production of TC-210, TCR2’s TRuC-T cell targeting advanced mesothelin-expressing cancer, to support demand for the anticipated Phase 2 clinical trial.